Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) headquartered in Boston, will host a conference call for the investment community to discuss the 2Q20 financial results on 10th August 2020 at 8:00 AM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.pieris.com
Earnings Expectation
Pieris Pharmaceuticals, Inc. is set to announce second quarter earning results on Monday 10th August 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, PIRS to report 2Q20 loss of $ 0.17 per share. For the full year, analysts anticipate top line of $ 37.39 million, while looking forward to loss of $ 0.62 per share bottom line.
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. Its lead respiratory program includes PRS-060, a drug candidate, which is in Phase I clinical trial that binds to IL-4Ra for the treatment of asthma and other inflammatory diseases; and lead immuno-oncology program comprises PRS-343, a bispecific protein that is in Phase I clinical trial for oncology diseases.
